External Source

First-in-human Phase I Results Of A Novel Btk Inhibitor Rocbrutinib In R/r Cll

2025 2:08
Synopsis
Jennifer Woyach, MD, The Ohio State University, Columbus, OH, shares findings from a first-in-human Phase I trial ...

You Might Also Like

Updates on the Phase I trial of rocbrutinib (LP-168), a novel BTKi, for the treatment of CLL 1:39
Updates On The Phase I Trial Of Rocbrutinib (lp-168), A Nove...
2024
Lyme Disease Roundtable
Lyme Disease Roundtable
2025
Evolution of BTK Inhibitors in CLL 5:06
Evolution Of Btk Inhibitors In Cll
2020
Targeting BTKi-resistant CLL using the 4th-generation BTK inhibitor rocbrutinib 1:54
Targeting Btki-resistant Cll Using The 4th-generation Btk In...
2025
Pirtobrutinib: The next generation of BTK inhibitors 1:18
Pirtobrutinib: The Next Generation Of Btk Inhibitors
2021
Novel Btk Inhibitor Heads to Phase III Trials in Chronic Lymphocytic Leukemia 2:48
Novel Btk Inhibitor Heads To Phase Iii Trials In Chronic Lym...
2011
Phase I/II BRUIN study: pirtobrutinib in patients intolerant to a covalent BTK inhibitor 1:08
Phase I/ii Bruin Study: Pirtobrutinib In Patients Intolerant...
2023
Tolerability of next-generation BTK inhibitors: acalabrutinib, zanubrutinib and pirtobrutinib 3:31
Tolerability Of Next-generation Btk Inhibitors: Acalabrutini...
2023
Phase 1 Study of Noncovalent BTK Inhibitor Docirbrutinib - Dr. Nitin Jain 7:58
Phase 1 Study Of Noncovalent Btk Inhibitor Docirbrutinib - D...
2025
Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL/SLL 3:00
Safety And Efficacy Of The Novel Btk Inhibitor Zanubrutinib ...
2020
Rilzabrutinib: a novel promising BTK inhibitor being explored in ITP 0:52
Rilzabrutinib: A Novel Promising Btk Inhibitor Being Explore...
2023
Download Options
Choose a download method below. All links open in new tabs.
Service Features Action
SaveFrom
MP4 & MP3 • HD Quality • Browser Extension Available
Download
Security Notice: These are third-party services. We recommend using antivirus software and being cautious of pop-up ads.